Annual EBIT
-$7.38 M
+$13.49 M+64.63%
31 December 2023
Summary:
GT Biopharma annual earnings before interest & taxes is currently -$7.38 million, with the most recent change of +$13.49 million (+64.63%) on 31 December 2023. During the last 3 years, it has risen by +$17.59 million (+70.44%). GTBP annual EBIT is now -145.24% below its all-time high of $16.32 million.GTBP EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$3.41 M
+$299.00 K+8.06%
30 September 2024
Summary:
GT Biopharma quarterly earnings before interest & taxes is currently -$3.41 million, with the most recent change of +$299.00 thousand (+8.06%) on 30 September 2024. Over the past year, it has dropped by -$995.00 thousand (-41.18%). GTBP quarterly EBIT is now -112.31% below its all-time high of $27.71 million, reached on 30 June 2015.GTBP Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$12.35 M
-$995.00 K-8.76%
30 September 2024
Summary:
GT Biopharma TTM earnings before interest & taxes is currently -$12.35 million, with the most recent change of -$995.00 thousand (-8.76%) on 30 September 2024. Over the past year, it has dropped by -$2.35 million (-23.51%). GTBP TTM EBIT is now -149.88% below its all-time high of $24.76 million, reached on 30 September 2015.GTBP TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GTBP EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +64.6% | -41.2% | -23.5% |
| 3 y3 years | +70.4% | +37.5% | +74.5% |
| 5 y5 years | +97.0% | +88.4% | +68.2% |
GTBP EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +87.1% | <-9999.0% | +81.0% | -67.2% | +78.5% |
| 5 y | 5 years | at high | +97.0% | <-9999.0% | +88.4% | -67.2% | +78.5% |
| alltime | all time | -145.2% | +97.0% | -112.3% | +98.5% | -149.9% | +95.1% |
GT Biopharma EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.41 M(-8.1%) | -$12.35 M(+8.8%) |
| June 2024 | - | -$3.71 M(+63.7%) | -$11.35 M(+17.8%) |
| Mar 2024 | - | -$2.27 M(-23.5%) | -$9.63 M(+30.5%) |
| Dec 2023 | -$7.38 M(-64.6%) | -$2.96 M(+22.6%) | -$7.38 M(-26.1%) |
| Sept 2023 | - | -$2.42 M(+21.3%) | -$10.00 M(-30.9%) |
| June 2023 | - | -$1.99 M(>+9900.0%) | -$14.46 M(-6.4%) |
| Mar 2023 | - | -$15.00 K(-99.7%) | -$15.45 M(-26.0%) |
| Dec 2022 | -$20.88 M(-63.6%) | -$5.58 M(-19.0%) | -$20.88 M(-37.3%) |
| Sept 2022 | - | -$6.88 M(+131.0%) | -$33.30 M(+4.5%) |
| June 2022 | - | -$2.98 M(-45.2%) | -$31.87 M(-5.6%) |
| Mar 2022 | - | -$5.44 M(-69.8%) | -$33.75 M(-41.1%) |
| Dec 2021 | -$57.30 M(+129.4%) | -$18.00 M(+230.1%) | -$57.30 M(+18.2%) |
| Sept 2021 | - | -$5.45 M(+12.2%) | -$48.49 M(+7.8%) |
| June 2021 | - | -$4.86 M(-83.2%) | -$44.98 M(-14.9%) |
| Mar 2021 | - | -$28.98 M(+215.1%) | -$52.89 M(+111.8%) |
| Dec 2020 | -$24.98 M(-31.6%) | -$9.20 M(+372.9%) | -$24.98 M(+50.3%) |
| Sept 2020 | - | -$1.95 M(-84.8%) | -$16.61 M(-62.2%) |
| June 2020 | - | -$12.76 M(+1092.9%) | -$43.99 M(+31.2%) |
| Mar 2020 | - | -$1.07 M(+28.1%) | -$33.53 M(-8.2%) |
| Dec 2019 | -$36.52 M(-85.4%) | -$835.00 K(-97.2%) | -$36.52 M(-5.8%) |
| Sept 2019 | - | -$29.32 M(+1169.2%) | -$38.78 M(-84.1%) |
| June 2019 | - | -$2.31 M(-43.0%) | -$244.12 M(-1.2%) |
| Mar 2019 | - | -$4.06 M(+31.2%) | -$246.97 M(-1.2%) |
| Dec 2018 | -$250.07 M(+84.5%) | -$3.09 M(-98.7%) | -$250.07 M(-1.1%) |
| Sept 2018 | - | -$234.66 M(+4450.3%) | -$252.87 M(+74.3%) |
| June 2018 | - | -$5.16 M(-28.0%) | -$145.06 M(+2.7%) |
| Mar 2018 | - | -$7.16 M(+21.5%) | -$141.19 M(+4.1%) |
| Dec 2017 | -$135.57 M(-930.5%) | -$5.89 M(-95.4%) | -$135.57 M(+3.7%) |
| Sept 2017 | - | -$126.86 M(+9772.1%) | -$130.73 M(+2089.1%) |
| June 2017 | - | -$1.28 M(-16.4%) | -$5.97 M(+286.5%) |
| Mar 2017 | - | -$1.54 M(+45.8%) | -$1.54 M(-60.5%) |
| Dec 2016 | $16.32 M(-282.8%) | -$1.05 M(-49.6%) | -$3.91 M(-85.2%) |
| Sept 2016 | - | -$2.09 M(-166.6%) | -$26.44 M(+8.7%) |
| June 2016 | - | $3.14 M(-180.5%) | -$24.32 M(-9866.3%) |
| Mar 2016 | - | -$3.90 M(-83.5%) | $249.00 K(-89.4%) |
| Dec 2015 | -$8.93 M(+272.6%) | -$23.59 M(<-9900.0%) | $2.34 M(-90.6%) |
| Sept 2015 | - | $32.00 K(-99.9%) | $24.76 M(+4.2%) |
| June 2015 | - | $27.71 M(-1630.0%) | $23.77 M(-689.4%) |
| Mar 2015 | - | -$1.81 M(+54.7%) | -$4.03 M(+68.3%) |
| Dec 2014 | -$2.40 M(-444.7%) | -$1.17 M(+22.4%) | -$2.40 M(+79.6%) |
| Sept 2014 | - | -$957.00 K(+918.1%) | -$1.33 M(+153.1%) |
| June 2014 | - | -$94.00 K(-46.0%) | -$527.00 K(+7.1%) |
| Mar 2014 | - | -$174.00 K(+59.6%) | -$492.00 K(-170.8%) |
| Dec 2013 | $695.00 K(-119.8%) | -$109.00 K(-27.3%) | $695.00 K(+64.3%) |
| Sept 2013 | - | -$150.00 K(+154.2%) | $423.00 K(-154.4%) |
| June 2013 | - | -$59.00 K(-105.8%) | -$777.00 K(-60.4%) |
| Mar 2013 | - | $1.01 M(-365.9%) | -$1.96 M(-44.2%) |
| Dec 2012 | -$3.51 M(+11.8%) | -$381.00 K(-71.8%) | -$3.51 M(-15.9%) |
| Sept 2012 | - | -$1.35 M(+8.7%) | -$4.18 M(+55.4%) |
| June 2012 | - | -$1.24 M(+129.6%) | -$2.69 M(+39.4%) |
| Mar 2012 | - | -$541.00 K(-48.3%) | -$1.93 M(-38.6%) |
| Dec 2011 | -$3.14 M(+26.7%) | -$1.05 M(-847.9%) | -$3.14 M(+17.8%) |
| Sept 2011 | - | $140.00 K(-129.0%) | -$2.67 M(-21.9%) |
| June 2011 | - | -$482.00 K(-72.5%) | -$3.42 M(+35.4%) |
| Mar 2011 | - | -$1.75 M(+207.4%) | -$2.52 M(+2.1%) |
| Dec 2010 | -$2.48 M(+123.6%) | -$571.00 K(-6.4%) | -$2.47 M(-0.6%) |
| Sept 2010 | - | -$610.00 K(-248.4%) | -$2.49 M(+23.8%) |
| June 2010 | - | $411.00 K(-124.1%) | -$2.01 M(-23.4%) |
| Mar 2010 | - | -$1.70 M(+191.1%) | -$2.62 M(+136.3%) |
| Dec 2009 | -$1.11 M(+5.5%) | -$585.00 K(+343.2%) | -$1.11 M(+42.5%) |
| Sept 2009 | - | -$132.00 K(-35.0%) | -$779.00 K(+53.3%) |
| June 2009 | - | -$203.00 K(+6.8%) | -$508.00 K(+47.7%) |
| Mar 2009 | - | -$190.00 K(-25.2%) | -$344.00 K(-67.3%) |
| Dec 2008 | -$1.05 M(-5.7%) | -$254.00 K(-282.7%) | -$1.05 M(-35.7%) |
| Sept 2008 | - | $139.00 K(-456.4%) | -$1.64 M(-18.4%) |
| June 2008 | - | -$39.00 K(-95.7%) | -$2.01 M(+28.4%) |
| Mar 2008 | - | -$898.00 K(+7.0%) | -$1.56 M(+40.0%) |
| Dec 2007 | -$1.12 M(-58.2%) | -$839.00 K(+264.8%) | -$1.12 M(-25.7%) |
| Sept 2007 | - | -$230.00 K(-156.8%) | -$1.50 M(-8.7%) |
| June 2007 | - | $405.00 K(-189.6%) | -$1.65 M(-35.3%) |
| Mar 2007 | - | -$452.00 K(-63.1%) | -$2.54 M(-4.8%) |
| Dec 2006 | -$2.67 M(+58.1%) | -$1.23 M(+228.4%) | -$2.67 M(+21.1%) |
| Sept 2006 | - | -$373.00 K(-24.2%) | -$2.20 M(+1.5%) |
| June 2006 | - | -$492.00 K(-15.2%) | -$2.17 M(+7.7%) |
| Mar 2006 | - | -$580.00 K(-23.6%) | -$2.02 M(+19.4%) |
| Dec 2005 | -$1.69 M(+46.1%) | -$759.00 K(+123.2%) | -$1.69 M(+122.8%) |
| Sept 2005 | - | -$340.00 K(+0.9%) | -$758.00 K(+176.6%) |
| June 2005 | - | -$337.00 K(+33.2%) | -$274.00 K(-37.7%) |
| Mar 2005 | - | -$253.00 K(-247.1%) | -$440.00 K(-30.3%) |
| Dec 2004 | -$1.16 M | $172.00 K(+19.4%) | -$631.00 K(-37.3%) |
| Sept 2004 | - | $144.00 K(-128.6%) | -$1.01 M(-22.0%) |
| June 2004 | - | -$503.00 K(+13.3%) | -$1.29 M(+21.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2004 | - | -$444.00 K(+117.6%) | -$1.06 M(+37.5%) |
| Dec 2003 | -$773.00 K(-4.7%) | -$204.00 K(+45.7%) | -$773.00 K(+15.4%) |
| Sept 2003 | - | -$140.00 K(-49.1%) | -$670.00 K(-18.9%) |
| June 2003 | - | -$275.00 K(+78.6%) | -$826.00 K(+16.7%) |
| Mar 2003 | - | -$154.00 K(+52.5%) | -$708.00 K(-12.7%) |
| Dec 2002 | -$811.00 K(-76.5%) | -$101.00 K(-65.9%) | -$811.00 K(-7.5%) |
| Sept 2002 | - | -$296.00 K(+88.5%) | -$877.00 K(-7.4%) |
| June 2002 | - | -$157.00 K(-38.9%) | -$947.00 K(-62.8%) |
| Mar 2002 | - | -$257.00 K(+53.9%) | -$2.54 M(-26.2%) |
| Dec 2001 | -$3.45 M(-26.9%) | -$167.00 K(-54.4%) | -$3.45 M(-27.2%) |
| Sept 2001 | - | -$366.00 K(-79.1%) | -$4.74 M(-14.3%) |
| June 2001 | - | -$1.75 M(+51.4%) | -$5.53 M(+12.4%) |
| Mar 2001 | - | -$1.16 M(-20.3%) | -$4.92 M(+4.0%) |
| Dec 2000 | -$4.73 M(+7.2%) | -$1.46 M(+25.5%) | -$4.73 M(+25.0%) |
| Sept 2000 | - | -$1.16 M(+1.4%) | -$3.78 M(+4.4%) |
| June 2000 | - | -$1.14 M(+18.0%) | -$3.62 M(-15.4%) |
| Mar 2000 | - | -$969.00 K(+90.0%) | -$4.28 M(-5.1%) |
| Dec 1999 | -$4.41 M(-37.9%) | -$510.00 K(-49.0%) | -$4.51 M(-26.1%) |
| Sept 1999 | - | -$1.00 M(-44.4%) | -$6.10 M(-16.4%) |
| June 1999 | - | -$1.80 M(+50.0%) | -$7.30 M(+9.0%) |
| Mar 1999 | - | -$1.20 M(-42.9%) | -$6.70 M(-9.5%) |
| Dec 1998 | -$7.10 M(+42.0%) | -$2.10 M(-4.5%) | -$7.40 M(+17.5%) |
| Sept 1998 | - | -$2.20 M(+83.3%) | -$6.30 M(+14.5%) |
| June 1998 | - | -$1.20 M(-36.8%) | -$5.50 M(-3.5%) |
| Mar 1998 | - | -$1.90 M(+90.0%) | -$5.70 M(+11.8%) |
| Dec 1997 | -$5.00 M(-15.3%) | -$1.00 M(-28.6%) | -$5.10 M(-10.5%) |
| Sept 1997 | - | -$1.40 M(0.0%) | -$5.70 M(-1.7%) |
| June 1997 | - | -$1.40 M(+7.7%) | -$5.80 M(-3.3%) |
| Mar 1997 | - | -$1.30 M(-18.8%) | -$6.00 M(-1.6%) |
| Dec 1996 | -$5.90 M(+7.3%) | -$1.60 M(+6.7%) | -$6.10 M(-3.2%) |
| Sept 1996 | - | -$1.50 M(-6.3%) | -$6.30 M(+1.6%) |
| June 1996 | - | -$1.60 M(+14.3%) | -$6.20 M(+3.3%) |
| Mar 1996 | - | -$1.40 M(-22.2%) | -$6.00 M(+11.1%) |
| Dec 1995 | -$5.50 M(+175.0%) | -$1.80 M(+28.6%) | -$5.40 M(+22.7%) |
| Sept 1995 | - | -$1.40 M(0.0%) | -$4.40 M(+15.8%) |
| June 1995 | - | -$1.40 M(+75.0%) | -$3.80 M(+40.7%) |
| Mar 1995 | - | -$800.00 K(0.0%) | -$2.70 M(+35.0%) |
| Dec 1994 | -$2.00 M(+17.6%) | -$800.00 K(0.0%) | -$2.00 M(+33.3%) |
| Sept 1994 | - | -$800.00 K(+166.7%) | -$1.50 M(+36.4%) |
| June 1994 | - | -$300.00 K(+200.0%) | -$1.10 M(-38.9%) |
| Mar 1994 | - | -$100.00 K(-66.7%) | -$1.80 M(0.0%) |
| Dec 1993 | -$1.70 M(+240.0%) | -$300.00 K(-25.0%) | -$1.80 M(+12.5%) |
| Sept 1993 | - | -$400.00 K(-60.0%) | -$1.60 M(+23.1%) |
| June 1993 | - | -$1.00 M(+900.0%) | -$1.30 M(+225.0%) |
| Mar 1993 | - | -$100.00 K(0.0%) | -$400.00 K(-20.0%) |
| Dec 1992 | -$500.00 K(0.0%) | -$100.00 K(0.0%) | -$500.00 K(0.0%) |
| Sept 1992 | - | -$100.00 K(0.0%) | -$500.00 K(0.0%) |
| June 1992 | - | -$100.00 K(-50.0%) | -$500.00 K(-350.0%) |
| Mar 1992 | - | -$200.00 K(+100.0%) | $200.00 K(-81.8%) |
| Dec 1991 | -$500.00 K(-200.0%) | -$100.00 K(0.0%) | $1.10 M(-168.8%) |
| Sept 1991 | - | -$100.00 K(-116.7%) | -$1.60 M(+220.0%) |
| June 1991 | - | $600.00 K(-14.3%) | -$500.00 K(-600.0%) |
| Mar 1991 | - | $700.00 K(-125.0%) | $100.00 K(-80.0%) |
| Dec 1990 | $500.00 K(0.0%) | -$2.80 M(-380.0%) | $500.00 K(+400.0%) |
| Sept 1990 | - | $1.00 M(-16.7%) | $100.00 K(>+9900.0%) |
| June 1990 | - | $1.20 M(+9.1%) | $0.00(-100.0%) |
| Mar 1990 | - | $1.10 M(-134.4%) | $500.00 K(0.0%) |
| Dec 1989 | $500.00 K(-600.0%) | -$3.20 M(-455.6%) | $500.00 K(-61.5%) |
| Sept 1989 | - | $900.00 K(-47.1%) | $1.30 M(+18.2%) |
| June 1989 | - | $1.70 M(+54.5%) | $1.10 M(+120.0%) |
| Mar 1989 | - | $1.10 M(-145.8%) | $500.00 K(-600.0%) |
| Dec 1988 | -$100.00 K(-150.0%) | -$2.40 M(-442.9%) | -$100.00 K(-116.7%) |
| Sept 1988 | - | $700.00 K(-36.4%) | $600.00 K(0.0%) |
| June 1988 | - | $1.10 M(+120.0%) | $600.00 K(+500.0%) |
| Mar 1988 | - | $500.00 K(-129.4%) | $100.00 K(-50.0%) |
| Dec 1987 | $200.00 K(-133.3%) | -$1.70 M(-342.9%) | $200.00 K(-113.3%) |
| Sept 1987 | - | $700.00 K(+16.7%) | -$1.50 M(+15.4%) |
| June 1987 | - | $600.00 K(0.0%) | -$1.30 M(+62.5%) |
| Mar 1987 | - | $600.00 K(-117.6%) | -$800.00 K(0.0%) |
| Dec 1986 | -$600.00 K(-25.0%) | -$3.40 M(-477.8%) | -$800.00 K(<-9900.0%) |
| Sept 1986 | - | $900.00 K(-18.2%) | $0.00(-100.0%) |
| June 1986 | - | $1.10 M(+83.3%) | -$500.00 K(-44.4%) |
| Mar 1986 | - | $600.00 K(-123.1%) | -$900.00 K(+12.5%) |
| Dec 1985 | -$800.00 K(-900.0%) | -$2.60 M(-750.0%) | -$800.00 K(-52.9%) |
| Sept 1985 | - | $400.00 K(-42.9%) | -$1.70 M(+88.9%) |
| June 1985 | - | $700.00 K(0.0%) | -$900.00 K(+125.0%) |
| Mar 1985 | - | $700.00 K(-120.0%) | -$400.00 K(-500.0%) |
| Dec 1984 | $100.00 K(-120.0%) | - | - |
| Dec 1984 | - | -$3.50 M(-391.7%) | $100.00 K(-97.2%) |
| Sept 1984 | - | $1.20 M(0.0%) | $3.60 M(+50.0%) |
| June 1984 | - | $1.20 M(0.0%) | $2.40 M(+100.0%) |
| Mar 1984 | - | $1.20 M | $1.20 M |
| Feb 1984 | -$500.00 K | - | - |
FAQ
- What is GT Biopharma annual earnings before interest & taxes?
- What is the all time high annual EBIT for GT Biopharma?
- What is GT Biopharma annual EBIT year-on-year change?
- What is GT Biopharma quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for GT Biopharma?
- What is GT Biopharma quarterly EBIT year-on-year change?
- What is GT Biopharma TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for GT Biopharma?
- What is GT Biopharma TTM EBIT year-on-year change?
What is GT Biopharma annual earnings before interest & taxes?
The current annual EBIT of GTBP is -$7.38 M
What is the all time high annual EBIT for GT Biopharma?
GT Biopharma all-time high annual earnings before interest & taxes is $16.32 M
What is GT Biopharma annual EBIT year-on-year change?
Over the past year, GTBP annual earnings before interest & taxes has changed by +$13.49 M (+64.63%)
What is GT Biopharma quarterly earnings before interest & taxes?
The current quarterly EBIT of GTBP is -$3.41 M
What is the all time high quarterly EBIT for GT Biopharma?
GT Biopharma all-time high quarterly earnings before interest & taxes is $27.71 M
What is GT Biopharma quarterly EBIT year-on-year change?
Over the past year, GTBP quarterly earnings before interest & taxes has changed by -$995.00 K (-41.18%)
What is GT Biopharma TTM earnings before interest & taxes?
The current TTM EBIT of GTBP is -$12.35 M
What is the all time high TTM EBIT for GT Biopharma?
GT Biopharma all-time high TTM earnings before interest & taxes is $24.76 M
What is GT Biopharma TTM EBIT year-on-year change?
Over the past year, GTBP TTM earnings before interest & taxes has changed by -$2.35 M (-23.51%)